Anti-Coagulants - Panama

Panama

In Panama, the revenue in the Anti-Coagulants market is estimated to reach US$15.85m by 2024.
Furthermore, a steady annual growth rate (CAGR 2024-2029) of 8.38% is anticipated, leading to a market volume of US$23.70m by 2029.
Comparing globally, United States is expected to generate the highest revenue in this market, with US$16,740.00m projected for 2024.
Panama's increasing aging population and rising incidence of cardiovascular diseases drive the demand for anti-coagulants in the country.

Key regions: Australia, Japan, United States, Germany, Europe

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Coagulants market in Panama has been experiencing growth in recent years.

Customer preferences: Patients in Panama are becoming more aware of the benefits of anti-coagulants and are increasingly seeking medical advice for the prevention of blood clots. As a result, there has been a rise in demand for anti-coagulant drugs in the country.

Trends in the market: One of the major trends in the Anti-Coagulants market in Panama is the increasing use of direct oral anticoagulants (DOACs). DOACs have become more popular due to their ease of use and lower risk of bleeding compared to traditional anti-coagulants. Another trend in the market is the growing use of anti-coagulants in the treatment of atrial fibrillation, which is a common heart condition in Panama.

Local special circumstances: Panama has a rapidly growing elderly population, which has contributed to the increase in demand for anti-coagulants. Additionally, the country has a high incidence of cardiovascular disease, which has further fueled the demand for anti-coagulant drugs.

Underlying macroeconomic factors: Panama has a stable economy and a strong healthcare system, which has allowed for the growth of the Anti-Coagulants market in the country. The government has also taken steps to improve healthcare access and affordability, which has helped to increase demand for anti-coagulants. Overall, the Anti-Coagulants market in Panama is expected to continue growing in the coming years.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.